Clinical Decision Support System for Quality Assurance in Potassium-Increasing Drug-Drug-Interactions
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 3,341
- 试验地点
- 2
- 主要终点
- Impact on serum potassium monitoring during potassium-increasing drug-drug-interactions
研究概览
简要总结
To investigate the impact of reminders for serum potassium monitoring and of hyperkalemia alerts during potassium-increasing drug-drug-interactions.
详细描述
The development of hyperkalemia during potassium-increasing drug-drug-interactions (DDIs) is associated with (i) unknown or elevated serum potassium level at onset of treatment and (ii) insufficient monitoring of serum potassium during therapy. However, potassium-increasing DDIs are frequently started despite an unknown or elevated serum potassium level, and monitoring intervals often exceed 48 hours.
This study investigates the impact of reminders for serum potassium monitoring and hyperkalemia alerts. Both reminders and alerts are displayed in the electronic patient chart of in-patients treated with potassium-increasing DDIs.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Health Services Research
- 盲法
- None
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
结局指标
主要结局
Impact on serum potassium monitoring during potassium-increasing drug-drug-interactions
时间窗: 1 year
Rate of serum potassium monitoring intervals of \< = 72 hours during potassium-increasing drug-drug-interactions in proportion to all serum potassium monitoring intervals during potassium-increasing drug-drug-interactions
次要结局
- Frequency of potassium-increasing drug-drug-interactions ordered in the presence of hyperkalemia(1 year)
- Frequency of transfers to the ICU during potassium-increasing drug-drug-interactions in function of the serum potassium level(1 year)
- Change in frequency distribution of serum potassium monitoring intervals(1 year)
- Frequency of hyperkalemia during potassium-increasing drug-drug-interactions(1 year)
- Response of physicians to the computer-based alerts and reminders(1 year)
- Frequency of death during potassium-increasing drug-drug-interactions in the presence or absence of hyperkalemia(1 year)